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Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) experiments are widely used to determine,
within entire genomes, the occupancy sites of any protein of interest, including, for example, transcription factors, RNA
polymerases, or histones with or without various modifications. In addition to allowing the determination of occupancy
sites within one cell type and under one condition, this method allows, in principle, the establishment and comparison of
occupancy maps in various cell types, tissues, and conditions. Such comparisons require, however, that samples be
normalized. Widely used normalization methods that include a quantile normalization step perform well when factor
occupancy varies at a subset of sites, but may miss uniform genome-wide increases or decreases in site occupancy. We
describe a spike adjustment procedure (SAP) that, unlike commonly used normalization methods intervening at the
analysis stage, entails an experimental step prior to immunoprecipitation. A constant, low amount from a single batch of
chromatin of a foreign genome is added to the experimental chromatin. This ‘‘spike’’ chromatin then serves as an internal
control to which the experimental signals can be adjusted. We show that the method improves similarity between rep-
licates and reveals biological differences including global and largely uniform changes.
[Supplemental material is available for this article.]
In chromatin immunoprecipitation (ChIP) followed by deep se-
quencing (ChIP-seq) (Barski et al. 2007; Johnson et al. 2007a;
Mikkelsen et al. 2007), chromatin is first treated, within intact
cells, with a cross-linking reagent such as formaldehyde. The cross-
linked chromatin is then isolated and fragmented, often by soni-
cation, and used as starting material for immunoprecipitations
with antibodies directed against the factors of interest. The im-
munoprecipitatedmaterial, containing the protein targeted by the
antibody as well as any DNA cross-linked to it, is heated to reverse
the crosslinks, the DNA is purified, and an amplified representa-
tion of this DNA is submitted to deep sequencing. Deep sequenc-
ing generates sequence ‘‘tags’’ of commonly 35 to ;100 nucleo-
tides (nt), which are then aligned onto the genome. Genomic
regions enriched in aligned tags over noise (variously defined in
differentworks) are interpreted as regions of factor occupancy. This
method has proven immensely powerful in characterizing chro-
matin organization, i.e., in identifying sites bound, for example, by
transcription factors, by histones carrying (or not) specific modi-
fications, or by RNA polymerases.
Apart from identifying regions of factor occupancy within
a single chromatin sample, ChIP-seq is invaluable for compar-
ing the level of occupancy at a set of loci (e.g., previously identified
targets of a specific transcription factor) between different chro-
matin samples from various cell types or tissues, from cells sub-
mitted to different conditions, or from cells at different de-
velopmental stages, etc. Unlike measurements of mature mRNAs,
such experiments inform on changes occurring at the very first
steps of gene expression, i.e., changes in chromatin structure and
gene transcription. In such experiments, however, reliable sample
normalization has proven difficult.
There are a number of different methods to normalize ChIP-
seq samples including scaling to total amounts of tags (i.e., nor-
malizing for sequencing depth), quantile normalization, and other
methods. Scaling to the total amount of sequence tags that can be
aligned onto the genome is usually the first step (for examples, see
Li et al. 2011; Landt et al. 2012; Le Martelot et al. 2012). Quantile
normalization is also broadly applied because it can reveal differ-
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ences at specific loci even in samples displaying relatively uniform
global differences at all enriched loci (for examples, see Rahl et al.
2010; Le Martelot et al. 2012). Scaling to total tag amounts and
quantile normalization can have very different effects, particularly
in cases of global differences; for example, if all regions enriched in
one sample are uniformly enriched to a higher or lower degree in
another sample. With just scaling to total amount of aligned tags,
these differences might persist, but their interpretation will be
difficult because scaling will not distinguish whether the differ-
ences result from technical experimental variations or from
genuine biological differences. With quantile normalization, on
the other hand, the distributions of the various samples are made
identical so that they can be easily compared, thus masking any
uniform changes, whether genuine or not, from one sample to
another.
Here we describe a spike adjustment procedure (SAP) de-
signed to allow comparison of occupancy levels for a set of loci
of interest. Unlike the above, this method addresses the problem
via an experimental procedure conducted prior to immunopre-
cipitation. It consists of adding a constant, low amount of a single
batch of foreign chromatin (e.g., human) as an internal control
to each sample of the chromatin of interest (e.g., mouse) before
immunoprecipitation. This allows adjustment of the signals
in each sample to the internal control. We show that unlike
only scaling to the total amount of aligned sequence tags or
quantile normalization, the SAP allows the scoring of global
and largely uniform changes when they result from biological
differences.
Results
To illustrate the approach, Figure 1A shows a hypothetical exper-
iment inwhich all ChIP-seq peaks are higher in a first sample (light
blue) compared with a second sample (purple). The global change
in peak size could in principle be the result of a biological differ-
ence, e.g., occupancy in the second example might be reduced
because of some change in cell metabolism; or it might reflect
a technical problem such as reduced immunoprecipitation effi-
ciency. In this hypothetical example, scaling to total amount of
tags maintains the differences because the total number of se-
quenced and aligned tags is roughly similar in both samples (Fig.
1B). In contrast, scaling followed by quantile normalization reveals
almost no differences between the samples (Fig. 1C), because the
peaks in the second experiment are more or less uniformly lower
than in the first. Thus, in this example the two methods give dif-
ferent results and do not allow one to distinguish between the two
scenarios, genuine biological difference or technical variability.
The two scenarios should be distinguishable, however, by ad-
justment to an internal reference. In panels D and E, the same
experiment is shown as in panel A but this time with a spike
signal, symbolized by the yellow bars. Replicates (or similar bi-
ological samples) displaying apparent different occupancy due to
technical problems would display a lower spike signal in the
second sample and, after normalization to this internal reference
by the SAP, little or no change (Fig. 1F). In contrast, biologically
different samples would reveal a global negative fold change
(Fig. 1G).
Addition of different percentages of human chromatin
to mouse chromatin
An internal reference is most useful when included as early as
possible in an experimental procedure. We therefore sought to
include the internal reference before the immunoprecipitation
step, which is one of the steps likely to generate variation fromone
sample to another in the ChIP-seq protocol. We tested the use-
fulness of adding spikes of human chromatin to mouse chromatin
samples for ChIP-seq experiments performed with two antibodies:
one directed against POLR3D (RPC4), a subunit of RNApolymerase
(Pol) III; and the other against POLR2B (RPB2), the second largest
subunit of Pol II (for a list of the samples used in this work and
their nomenclature, see Table 1). Both antibodies are directed
against peptides that are 100% conserved in mouse and human
Pol III and Pol II, respectively. We first focused on experiments
using the anti-POLR3D antibody and tested mixing different
amounts of human chromatin with the mouse chromatin, with
the aim of using the smallest possible amount of human chro-
matin so as to avoid unnecessary contamination of the mouse
sample, and yet obtaining a robust signal on a sufficient number
of human genes.
The various mixtures were used for ChIP-seq and the
resulting 100-nt-long sequence tags were aligned with both the
mouse (NCBI37/mm9) and human (GRCh37/hg19) genomes.
Supplemental Table S1, A and B, lists the tag counts that aligned
to the mouse genome, the human genome, or to both genomes
(ambiguous tags). Adding 2.5%, 5%, or 10% human chromatin
derived from HeLa cells resulted in an increase in the number
of reads aligning to the human genome, as expected, but had
little influence on the amount of ambiguous reads, indicating
that most of the ambiguous reads originate from the mouse
chromatin, which is not surprising since this chromatin repre-
sents in all cases most of the material. Moreover, the ambiguous
tags represented only a small proportion of the tags mapping to
human Pol III regions (see Supplemental Table S1B [sheet 2], last
column) such that there was little loss of sensitivity in the
human signal due to the exclusion of tags that cannot be un-
equivocally mapped to the mouse or human genomes. For
subsequent analyses, we thus used 2.5% human chromatin,
as this amount produced a usable signal on human genes (see
below).
Spiking samples allows quality control
Figure 2 summarizes the steps in the SAP. After tag alignment to the
human and the mouse genomes and removal of ambiguous tags,
we first tested whether the human spike signal can be used for
quality control evaluation. Indeed, since the human chromatin
added to the experimental mouse samples is constant from one
sample to another, the quality of the human signal should in
principle attest to the technical quality of the experiment, unlike
experimental mouse samples where the mouse signal may vary
according to biological differences. We thus compared a sample
generated with our standard protocol (90_R1) (see Table 1) to
a ‘‘poor’’ sample (97.5_P1) (see Table 1) in which we deliberately
contaminated the immunoprecipitated material by adding back
1.5% of the supernatant obtained after immunoprecipitation.
Figure 3 shows, for each of these two spiked-in samples, a mean-
difference scatter plot comparing spike human tag counts in 400-
bp genomic bins obtained in the ChIP versus the input. The red
dots indicate bins that overlap with what we refer to hereafter as
‘‘Pol III loci,’’ i.e., annotated Pol III genes (whether occupied by Pol
III or not) as well as previously identified Pol III–occupied loci (see
Table S2 in Renaud et al. 2014). With the standard protocol (upper
panel), many of the bins overlapping with spike human Pol III loci
showed strong enrichment in the ChIP sample with respect to the
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input. In contrast, the poor sample (lower panel) showed almost
no enrichment. Thus, the amount of signal in human Pol III loci
reflects sample quality, as expected, and can be used for quality
control. A quantitativemetric to characterize signal content can be
the percentage of tags aligning in gene regions. Indeed, as shown
in Supplemental Table S1B (sheet 2), the percentage of human tags
Figure 1. Normalization can obscure global effects. (A) Schematic representation of peaks obtained after ChIP-seq in a hypothetical example where all
peaks are uniformly diminished in the second (purple) sample compared with the first (light blue). These samples can represent a replicate experiment, in
which case the overall decrease observed in the second sample is the result of experimental variation, or they can represent experiments performed with
samples collected under different conditions, in which case the global decrease might reflect a biological difference. No spike chromatin is included. (B)
Normalization by scaling to total number of tags aligned onto the genome (i.e., normalization for sequencing depth) showing tag counts (top) and log2
fold change (bottom). In this hypothetical example, the number of tags aligned onto the genome is quite similar in both samples, and this type of
normalization indicates a general decrease for each peak in the second sample, whether the two samples are biologically different (and thus should indeed
indicate a protein occupancy decrease in sample 2) or similar (and thus should in fact display similar signals). (C ) Normalization by scaling followed by
quantile normalization showing tag counts (top) and log2 fold change (bottom). In this example, the second step—quantile normalization—will equalize
the sample distributions whether the samples are biologically different or not, because the decrease in sample 2 is uniform. In D and E, spike chromatin is
included in the sample and gives rise to signals symbolized by the yellow bars. (F,G) Normalization by scaling followed by spike adjustment showing tag
counts (top) and log2 fold change (bottom). In F, the spike adjustment factor increased the signals in sample 2 by a factor of about two, in G, the spike
adjustment factor decreased the signal in sample 2 by a factor of about 0.8 (see yellow bars). Spike adjustment reveals whether the samples are in fact
similar (example in F) or are in fact biologically different (example in G).
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in human Pol III loci was 8.7- to 16.7-fold lower for the poor
97.5_P1 sample compared with the standard 97.5_R1 or any of the
other standard replicate (R) samples (column G). Together with
visual inspection of scatter plots as shown above, this information
can be used to identify samples that should be discarded (and ex-
periments that should be redone).
The next step after assessing sample quality consisted in scal-
ing the samples relative to the total number of aligned tags (scaling
for sequencing depth) in each experiment, which was performed
separately for the mouse and human tags (Fig. 2, step 2). We then
selected signal loci (step 3; see Methods) and calculated scores for
the human sample and preliminary scores for the mouse sample
(step 4). We then used the sample-to-sample differences in human
signals to compute a spike adjustment factor for each sample. This
spike adjustment factor was applied to the preliminary scores of the
mouse Pol III loci (for a list of these loci, see Table S3 in Renaud et al.
2014) to obtain final scores (step 5; see Methods).
Effect of sonication on the spike signal
As sonication is performed before addition of the spiking material,
a possible problem with the SAP might arise as a result of sonica-
tion of the human and mouse samples to different average frag-
ment sizes. This is illustrated in Figure 4A. In this example, the
human chromatin, which is from a single batch, is sonicated to an
average size of 500 bp. In contrast, the first mouse chromatin is
sonicated to a larger average size (upper panel), whereas the second
sample is sonicated to a smaller average size (lower panel). Size
selection of DNA fragments from 200 to 400 bp during library
preparation (indicated by the rectangle) would result in a smaller
percentage ofmouse chromatin in the first case comparedwith the
second case. This problem should be in large part circumvented by
the first normalization step, in which we scale independently
the human and mouse signals to the total number of aligned se-
quence tags.
To directly test the effects of different average sizes of the
mouse sample, we sonicated mouse chromatin for five, 10, and 15
cycles. As expected, increasing the number of sonication cycles
resulted in shorter average mouse chromatin fragment lengths, as
visualized after analysis on a Bioanalyzer 2100 from Agilent (Fig.
4B, upper panel, lanes S5, S10, S15) or after agarose gel electro-
phoresis (lower panel). Figure 4B also shows the human spike
chromatin, whichwas fragmented less completely than themouse
samples but nevertheless contained an abundance of fragments
<1000 bp.
Despite the variable length distributions of the mouse chro-
matin samples, the SAP did not disrupt the data and sample
alignments remained very high in all cases, as illustrated by the
scatter plots in Figure 4C (for Pearson and Spearman correlations,
see Figure 4 legend). Thus, spike adjustment is quite impervious to
differences in sample sonication.
Spike adjustment both improves similarity between biological
replicates and reveals biological differences
To test the usefulness of the SAP to both improve similarity be-
tween replicates and reveal biological differences, we made use of
two experiments that are part of an independent study (NBonhoure,
V Praz, RD Moir, IM Willis, and N Hernandez, unpubl.). In these
experiments, which were performed at different times, before and
after upgrade of the sequencer, butwith the same batches ofmouse
and human chromatin, we compared Pol III occupancy in the liver
of wild-type (WT) mice (samples mR1_WT and mR2_WT) (see
Table 1) and mice lacking theMaf1 gene (mR1_KO and mR2_KO).
MAF1 is a repressor of Pol III transcription, both in yeast (Pluta
et al. 2001; Upadhya et al. 2002) and in mammalian cells (Reina
et al. 2006; Johnson et al. 2007b; Rollins et al. 2007), which
prevents transcription complex assembly by binding to Pol III as
well as to BRF1, a member of the Pol III preinitiation complex
(Desai et al. 2005; Oficjalska-Pham et al. 2006; Reina et al. 2006;
Goodfellow andWhite 2007; Vannini et al. 2010). In the absence
of MAF1, one might expect a difference in Pol III occupancy at
Pol III loci.
We first compared the replicates before and after spike ad-
justment (step 5 in Fig. 2). As shown in the scatter plots in Figure 5,
A and B, the scores for Pol III–occupied loci were closer to the x = y
Table 1. Samples used in this work
Sample name Mouse chromatin (%) Human chromatin (%) Antigen Amount of antibody used (mL) Number of sonication cycles
97.5_R1 97.5 2.5 POLR3D 10 10
95_R1 95.0 5 POLR3D 10 10
90_R1 90.0 10 POLR3D 10 10
97.5_P1 97.5 2.5 POLR3D 10 (1.5% supernatant added back) 10
97.5_S5 97.5 2.5 POLR3D 10 5
97.5_S10 97.5 2.5 POLR3D 10 10
97.5_S15 97.5 2.5 POLR3D 10 15
mR1_WT 97.5 2.5 POLR3D 10 10
mR1_KO 97.5 2.5 POLR3D 10 10
mR2_WT 97.5 2.5 POLR3D 10 10
mR2_KO 97.5 2.5 POLR3D 10 10
RPB2_95 95 5 POLR2B 10 10
RPB2_90 90 10 POLR2B 10 10
The numbers in the names (97.5, 95, or 90) refer to the percentage of mouse chromatin in the sample (the rest correspond to human chromatin). R1 or
R2 refer to technical replicates (separate immunoprecipitations performed with the same chromatin sample); P1 refers to a ‘‘poor’’ sample in which the
immunoprecipitation conditions were changedwith the aim of reducing efficiency; and S5, S10, and S15 refer to different sonication conditions. mR1_WT
and mR2_WT, as well as mR1_KO and mR2_KO, are in each case replicate ChIP-seq performed at a 10-mo interval with the same batch of wild-type (WT)
and Maf1 knockout (KO) mouse liver chromatin. The replicates were spiked with the same batch of human chromatin. All samples were immunopre-
cipitated with antibodies directed against the POLR3D subunit of Pol III, except for the samples labeled ‘‘RPB2,’’ which were immunoprecipitated with
antibodies directed against the POLR2B subunit of Pol II.
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line after (black) than before (orange) spike adjustment, both for
the replicate samples fromWTmice (panel A) and for those of the
Maf1 KO mice (panel B).
We then compared the four samples using scaling to total
number of tags (Fig. 1, cf. A and B), scaling and quantile nor-
malization (Fig. 1, cf. A and C), or scaling and spike adjustment
(Fig. 1, cf. D–G). Figure 5, C through E, shows the resulting box-
plots of the occupancy scores on Pol III loci in WT (green) and
Maf1 KO mice (blue), in the first (light colors) or second (dark
colors) experiments. After just scaling (panel C), the average and
median occupancy were in each case higher in the Maf1 KO
samples compared with the corresponding WT sample. However,
the average andmean of the firstMaf1 KO sample (mR1_KO)were
very similar to the average and mean of the second WT sample
(mR2_WT; cf. the second and third box plots), making the results
difficult to interpret. Upon scaling and quantile normalization,
the distributions of all samples became similar, as expected (panel
D). In contrast, the SAP not only remarkably improved the
agreement between replicates, in particular for the KO samples,
but also revealed a clear difference between the WT and KO
samples, with higher average Pol III occupancy in the KO samples
(panel E). This was also evident in the empirical cumulative dis-
tribution function (ECDF) graphs (panels F–H), showing identical
distributions for all samples after scaling andquantile normalization
(panelG), butmore similar distributions for the twoWTand the two
KO samples, as well as better separation of the WT and KO sample
pairs, for the samples normalized with SAP (cf. panels F and H).
To examine the effect of scaling and quantile normalization
versus the SAP on a locus per locus basis, we performed a differ-
ential analysis with the two sets of normalized scores. The results
are displayed asmean-difference plots in Figure 5, I and J, with the
scores showing a significant difference in the WT versus Maf1
KO samples in yellow (P# 0.01) and red (0.01 < P# 0.05). With the
scaling and quantile normalization method (panel I), 34 loci
had significantly different occupancy, but the minimum false-
discovery rate (FDR = 0.045) was close to the cutoff 0.05, and there
was a roughly equal number of loci with higher and lower scores
in the Maf1 KO compared with the WT samples. With the SAP,
490 loci scored as having significantly different Pol III occupancy,
and all but one (with a very low score) showed higher Pol III oc-
cupancy in the KO compared with the WT samples (panel J). Thus,
the SAP both improves similarity of replicates and reveals biological
differences, even when these are quite uniform for all loci.
Figure 2. Schematic diagram summarizing the SAP. The main steps,
i.e., examination of sample quality, scaling to total amount of genome-
aligned tags, selection of signal genes, score calculation, and spike ad-
justment, are numbered.
Figure 3. The spike chromatin can be used for quality control. Mean-
difference scatter plot of human Pol III genome bin counts (in log scale).
Red dots indicate genomic bins that overlap with Pol III loci. The genome
was binned into 400-bp bins (corresponding to a typical Pol III gene
length [;100 bp] extended by 150 bp in both the upstream and
downstream directions). Zero-count bins were filtered out prior to plot-
ting. (A) An example of a good-quality sample (90_R1). (B) An example of
a poor-quality sample (97.5_P1).
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Improvement of Pol II ChIP-seq biological replicate similarity
by spike adjustment
In the examples above, we used a method to calculate preliminary
scores (Fig. 2, step 4) that is tailored to ChIP-seq experiments where
the total genomic target of the factor of interest is relatively small and
where, therefore, the tags mapping to this target represent a small
percentage of the total amount of tags aligning onto the genome, as
is the case for many factors (Landt et al. 2012). Indeed, for Pol III
occupancy, tagsmapping to known targets
for bothhuman andmouse Pol III (Canella
et al. 2010, 2012; Renaud et al. 2014) rep-
resented 0.01%–1% of the total number
of aligned tags (see Supplemental Table
S1A,B). To determine whether the spike
adjustment method might be more gen-
erally applicable, we applied it to chroma-
tin samples immunoprecipitated with
anti-POLR2B antibodies, and we calcu-
lated preliminary scores around TSSs using
the SPP software (https://sites.google.com/
a/brown.edu/bioinformatics-in-biomed/
spp-r-from-chip-seq) (Kharchenko et al.
2008). The samples, referred to as RPB2_95
and RPB2_90 (see Table 1), contained dif-
ferent percentages of human chromatin
(which was managed in the analysis by
the species-specific scaling) (step 2 in
Fig. 2) but otherwise were derived from
the same batch of mouse chromatin
and processed similarly (for numbers of
tags aligned to mouse and human ge-
nomes, see Supplemental Table S2A,B)
and can thus be considered technical
replicates. We calculated Pol II scores
in mouse regions extending from 250
to +250 bp around 11,217 annotated
TSSs selected to be separated by at least
1000 bp from any other annotated TSS or
polyadenylation site (see Le Martelot et
al. 2012).
Figure 6A, left and right panels,
show ECDF graphs of the samples after
SPP score calculation, or after SPP score
calculation and spike adjustment. The
replicates were of high quality such that
they were very close even before spike
adjustment. Nevertheless, spike adjust-
ment decreased the Kolmogorov-Smirnov
distance between the two samples by
more than half. The improvement is also
visible in the scatter plot in Figure 6B,
showing a tightening of the scores along
the x = y line after spike adjustment.
Thus, spike adjustment performs well
not only for samples immunoprecipi-
tated with an antibody targeting Pol III,
but also for samples immunoprecipitated
with an antibody targeting Pol II. More-
over, it can be applied to scores calculated
by a method other than the one we spe-
cifically developed for Pol III occupancy.
As further discussed below, this method is thus likely to be widely
applicable.
Discussion
We describe a normalization method for ChIP-seq experiments
that is not confined to computational treatment of the data but
includes an experimental step, namely the addition of an internal
reference to each sample. This internal reference consists of a small
Figure 4. The SAP tolerates sample-to-sample differences of average chromatin fragment length. (A)
Illustration of two hypothetical cases. (Top) The mouse chromatin sample (blue) is sonicated to an
average size >500 bp; (bottom) the average size is <500 bp. The human chromatin (red) used to spike
the samples is from the same batch and has an average size of 500 bp. Size selection from 200 to 400 bp
is expected to result in a smaller proportion of mouse chromatin in the first case than in the second case.
(B) Size representation obtained by fragment analyzer (top) and 1% agarose gel electrophoresis (bot-
tom) of three mouse chromatin samples sonicated for 5 (S5), 10 (S10), and 15 (S15) cycles of 10 sec, as
indicated above the lanes. The position of DNA size markers (in bp) is indicated on the left. The last lane
shows the human chromatin spike sample. (C ) Scatter plots showing the relation ofmouse Pol III loci scores
before and after spike adjustment for the three pairs of samples sonicated for different amounts of time. The
Pearson and Spearman correlations before and after spike adjustment were as follows: 97.5_S5 versus
97.5_S10, 0.9927!0.9935 and 0.9678!0.9653; 97.5_S5 versus 97.5_S15, 0.9900!0.9885 and
0.9728!0.9663; and 97.5_S10 versus 97.5_S15, 0.9917!0.9926 and 0.9626!0.9636.
Bonhoure et al.
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amount of chromatin (spike) from a different species than the
chromatin being tested, but a species close enough that the factors
of interest share conserved epitopes, in our case human chromatin
added to mouse chromatin. The internal reference is mixed with
the experimental sample and undergoes all experimental steps
following fragmentationof the chromatin, i.e., immunoprecipitation,
library preparation, and sequencing. The method is related, in its
principle of introducing an internal reference into each sample, to the
method recently described by Loven et al. (2012) to normalize RNA-
seq data. In that case, a synthetic RNA standard is added to each RNA
sample to be analyzed in proportion to the starting number of cells,
thus allowing quantification of RNA relative to starting cell number
(Loven et al. 2012).
We show that the spike signal allowsquality control. Indeed, it is
in principle affected only by experimental (rather than biological)
variations, and thus allows one to pinpoint dubious experimental
samples that should be considered with circumspection and possibly
discarded. For samples passing this quality control test, the SAP both
improves similarity between replicates, without disrupting the dis-
tribution of the data, and reliably reveals true biological differences.
Thus, on one hand, spike adjustment prevents the erroneous per-
ception of differences when there are no genuine differences in
protein occupancy; i.e., it reduces false-positive calls. On the other
hand, it allows reliable recognition of real differences in occupancy;
i.e., it also reduces false-negative calls.
The amount of spike material to be added to the sample
should be as low as possible to give a robust spike signal and yet to
contribute as few ambiguous tags as possible. This amount will
vary with sequencing depth and size of the ChIP genomic target
(for an exploration of this relationship, see Methods). We tested
adding different amounts of human ‘‘spike’’ chromatin to the
mouse chromatin and found that for our experiments, 2.5% was
sufficient to provide a robust spike signal (Fig. 3). It might be ad-
vantageous to use asmuch as 5% spike chromatin because thismay
allow the ‘‘rescue’’ of poorer quality experimental samples. On the
other hand, an increase in spike material might result in an in-
crease in the number of ambiguous tags, i.e., tags that map to both
the mouse and the human genomes, and this in turn might affect
the mouse scores, especially for lowly occupied genes near the
detection limit and in genes highly conserved in mouse and
humans, as these tags are removed from the analysis. Thus, for
analyses focusing on individual gene scores rather than on score
distributions, it may be beneficial to add the ambiguous tags to the
mouse tags, their most likely origin given that most of the starting
material is mouse chromatin, with some attention to cases where
a highly expressed spiked-in gene shares tags with a lowly
expressed mouse gene.
The spike chromatinwas added to the sample chromatin after
the sonication step. Indeed, although it would in principle be
preferable tomix the twomaterials before sonication, the difficulty
of precisely quantifying tissue, cells, or the viscous presonication
chromatin makes it impractical. Thus, when samples with differ-
ent fragment size distributions are mixed with the same batch of
sonicated spike chromatin, the proportion of spike chromatin
fragments will differ in different samples. This is in principle cor-
rected by the scaling to total number of tags, as this scaling is per-
formed separately for the human and the mouse tags. Indeed, we
found that the SAP gave very similar results for chromatin samples
varying up to threefold in sonication time.
We tested the SAP in the study of Pol III occupancy, because this
is one case where genome occupancy is likely to vary in a global
manner and where current normalization methods are prone to
failure. Indeed, Pol III transcription is, for example, elevated in
cancer cells, and is globally diminished under certain conditions
such as nutrient deprivation or other kinds of stress (for reviews,
see White 2004; Goodfellow and White 2007; Gjidoda and Henry
2013). In yeast, a global Pol III transcription decrease upon nutrient
deprivation is accompanied by a general decrease in Pol III occu-
pancy at Pol III loci (Roberts et al. 2003, 2006; Oficjalska-Pham et al.
2006). Consistent with such global regulation, most known regula-
tors of Pol III transcription act on general transcription factors used
by all Pol III promoters such as TFIIIB or, in the case of the general
Pol III repressor MAF1, on the polymerase itself (for reviews, see
Geiduschek and Kassavetis 2006; Willis and Moir 2007; Ciesla and
Boguta 2008). Indeed,we showhere that deletion of themouseMaf1
gene leads to generally increased Pol III occupancy at Pol III loci in
a tissue, the mouse liver. Such global changes in chromatin occu-
pancy are likely to bemore common than generally appreciated. For
example, it has recentlybeen shown that an increase inMYCprotein
leads to a general ‘‘transcriptional amplification,’’ which is accom-
panied by increased MYC and Pol II occupancy at most promoters
(Lin et al. 2012; Nie et al. 2012). The SAP canmake detection of such
global changes by ChIP-seq experiments more reliable.
Although we developed the SAP for the specific purpose
of comparing Pol III occupancy under various biological condi-
tions, the method is not limited to this particular application.
We have also shown that the SAP improved similarity of replicate
samples for Pol II ChIP-seq scores calculated with the SPP software;
spike adjustment can thus be applied for ChIP-seq results other
than Pol III and for scores calculated by different methods. More-
over, although the SAP is in principle limited by the availability of
an antibody capable of recognizing the target of interest in different
species, such antibodies are in fact common for many factors widely
studied by ChIP-seq experiments, such as RNA polymerases and
other members of the general transcription machinery, or histones
and their modifications, as these are in general highly conserved in
different species. Indeed, in this work we used antibodies that rec-
ognize human and mouse Pol III as well as human andmouse Pol II,
and showed that for both of these factors, themethod performs well.
We have used human chromatin to spike mouse chromatin, but the
reverse can be done, and chromatin from other species could be used
for spiking according to needs, as long as the epitopes in the targets
Figure 5. Spike adjustment improves similarity between replicates and reveals genuine differences in Pol III occupation. (A,B) Scatter plots showing the
relation of Pol III loci scores between the twoWT (A) and the twoMaf1 KO (B) replicate samples before (orange) and after (black) spike adjustment. The red
line corresponds to x = y. (C–E) Boxplot representations of the Pol III loci score distributions for the two WT samples (light and dark green, mR1_WT and
mR2_WT) and the twoMaf1 KO samples (light and dark blue, mR1_KO and mR2_KO). The scores were normalized to total number of tags aligned onto
the genome (C ) followed by either quantile normalization (D) or spike adjustment (E). (F–H) Empirical cumulative frequency distributions functions
(ECDFs) of the log scores of the indicated distribution. Samples were normalized to the total number of tags aligned onto the genome (F) followed by
either quantile normalization (G) or spike adjustment (H). The Kolmogorov-Smirnov (KS) distance for the twoWT (green lines) and the twoMaf1 KO (blue
lines) samples is shown at the bottom right of each panel. (I,J) Mean difference scatter plots illustrating Pol III occupancy inWT andMaf1 KO livers. Samples
were normalized to the total number of tags aligned onto the genome followed by quantile normalization (I), respectively by spike adjustment (J). Scores
for WT and KO conditions are the average of the two replicates. Loci with scores showing a significant difference in the WT versus Maf1 KO samples are
represented with yellow (P# 0.01) and red (0.01<P# 0.05) dots.
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studied are conserved. Further, when using cells or organisms ex-
pressing tagged proteins combined with antibodies directed against
the tags, an internal control chromatin, i.e., chromatin from cells
expressing a chosen factor carrying the same tag, can be designed.
The spike adjustment method should thus be widely applicable.
Methods
Spiked mouse ChIP
Perfused C57BL/6 mice liver were homogenized in 4 mL of PBS
containing 1% of formaldehyde and left in the same buffer for cross-
linking for a total of 10 min. Nuclei were isolated as described in
Ripperger and Schibler (2006). Nuclear lysis was performed in 1.2mL
of 50mMTris/HCl (pH 8.1), 10mMEDTA, 1% SDS, 50 mg/mL PMSF,
1 mg/mL leupeptin. The nuclear lysate was then supplemented with
0.92mLof 20mMTris/HCl (pH 8.1), 150mMNaCl, 2mMEDTA, 1%
Triton X-100, 0.01% SDS, 50 mg/mL PMSF, 1 mg/mL leupeptin and
sonicated with a Branson SLPe sonicator during 10 cycles of 10 sec at
50% amplitude, resulting in an average fragment size between 300
and 1000 bp. Between each sonication cycle, the chromatin was kept
in an ice-cold bath during 20 sec. The samples 97.5_S5 and 97.5_S15
were sonicated with five and 15 cycles,
respectively, of 10 sec each. Chromatin
samples from three mice were pooled
and de-cross-linked, and an aliquot was
extracted for DNA quantification. Human
HeLa cell chromatin was prepared as de-
scribed in Canella et al. (2010), and DNA
concentration was assessed.
ChIPs were performed with 30.8 mg
of total DNA in the appropriate mouse/
human chromatin ratio and 10 mL of rab-
bit serum immunized against a peptide
100% conserved in human and mouse
POLR3D (CS681 antibody, C-terminal
peptide CSPDFESLLDHKHR) (Chong et al.
2001). This antibody has been used ex-
tensively for ChIP-seq experiments, in
both human and mouse cells (Canella
et al. 2010, 2012; Renaud et al. 2014). For
the anti-Pol II ChIPs, the commercial
antibody anti-POLR2B (H-201; catalog
no. sc-67318, Santa Cruz Biotechnology)
recognizing human, mouse, and rat
POLR2B was used. The ChIPs were per-
formed as described previously in Forsberg
et al. (2000) and Dhami et al. (2010) with
a fewmodifications. Briefly, the chromatin
samples were incubated with the anti-
bodies overnight at 4°C. The next day, 20
mL of protein A–sepharose beads (CL4BGE
Healthcare) was added and the samples
were further incubated for 3 h. The beads
were next washed once with 20 mM Tris/
HCL (pH 8.1), 50 mM NaCl, 2 mM EDTA,
1% Triton X-100, 0.1% SDS; twice with 10
mM Tris/HCL (pH 8.1), 250 mM LiCl,
1 mMEDTA, 1% NP-40, 1% deoxycholic
acid; and twice with TE buffer 13 (10 mM
Tris-Cl at pH 7.5. 1 mM EDTA). Bound
material was then eluted from the beads
in 300 mL of elution buffer (100 mM
NaHCO3, 1%SDS), treated firstwith RNase
A (final concentration8mg/mL) during 6h
at 65°C and then with proteinase K (final concentration 345 mg/mL)
overnight at 45°C. The next day, the samples were purified with
a PCR clean-up kit from Macherey Nagel and eluted in 50 mL of
elution buffer. Sample 97.5_P1 was prepared as described above ex-
cept that 1.5% of the immunoprecipitation supernatant was added
back to the bead-eluted immunoprecipitated material.
Ultra-high-throughput sequencing
Ten nanograms of DNA from each ChIP was next used to prepare
sequencing libraries according to the Illumina ChIP-seq DNA
sample prep protocol (Illumina, catalog no. IP-102-1001), except
that size selection of the samples was performed after, rather than
before, library amplification. Sequencing libraries were loaded
onto one lane of a HiSeq 2000 flow cell and sequenced at 100 cy-
cles. For each condition, we sequenced input chromatin sample
and the corresponding ChIP sample(s).
Analysis method principle
Samples contain a fixed amount of added-in reference (human)
chromatin (spike). We assume that any variation in the back-
ground-adjusted counts from this constant reference chromatin
Figure 6. Spike adjustment improves the similarity of two Pol II ChIP-seq replicate experiments. (A) ECDFs
of the scores of the indicated distributions. Preliminary scoreswere computed around the TSS (6250bp)with
the SPP software. The KS distance is shown at the bottom right of each panel. (Dark line) RPB2_90 sample;
(light line) RPB2_95 sample. (B) Scatter plots showing the relation between the RPB2_90 and RPB2_95 scores
before (orange dots) and after (black dots) spike adjustment. The red line corresponds to x = y.
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reflects technical experimental variations and that, therefore, a scal-
ing factor estimated from the reference chromatin can be used to
adjust tag counts in the experimental chromatin. Tags are assigned to
the reference (human) or the experimental (mouse) chromatin and
analyzed separately, each according to themodel below. For both, the
input samples are used for computing background-adjusted counts.
To simplify notation, we consider that there is only one ChIP sample
per condition, indicated by the index k.We assume, as in Enroth et al.
(2012), that tags in theChIP sample come from the following sources:
specific binding to the antibody (true enrichment), nonspecific
binding (to the antibody and the beads), and random noise.
The genome is partitioned into segments roughly the size of
the regions of interest. Tag counts are computed for all such ge-
nomic segments. The probability distribution for the nonspecific
tag counts is denoted as xi, where i indicates a genomic segment (or
xi,k for segment i in sample k). The distribution of the specific tags
for condition k is denoted as yi,k. The observed counts for the
segments in the input sample are denoted as bi,k and are amultiple
of xi,k with experimental errors ei,k:
bi;k =gkxi;k + ei;k: ð1Þ
For the ChIP samples, the observed counts zi,k are given by
zi;k =akyi;k +bkxi;k + ei;k; ð2Þ
where akyi,k are the specific tag counts corresponding to protein
occupancy scores (signal), xi,k is the nonspecific tag distribution, as
in Equation 1, and ei,k is random noise. Equation 1 is used to es-
timate bkxi,k in Equation 2.
Analysis method principle: preliminary score calculation
for Pol III data
Our goal is to estimate the signal counts in regions of interest,
namelyakyi,k in Equation 2. A key assumption is that the nonspecific
segment counts in ChIP are proportional to their observed input
segment counts. When most segments are not enriched by ChIP,
this implies a linearity of segment counts in the ChIP sample
versus the input sample. As shown in Supplemental Figure S1,
this is indeed the case for our data, in which tags mapping to the
regions of interest (400-bp bins overlapping with ‘‘Pol III loci,’’
i.e., annotated Pol III genes [whether occupied by Pol III or not] as
well as other previously identified Pol III–occupied loci; for the
list, see Tables S2 [human loci] and S3 [mouse loci] in Renaud et al.
2014) represent a small percentage of the total amount of tags
aligning onto the genome (0.01%–1%) (see Supplemental Table
S1A,B). To adjust for variation in the amount of specific counts in
segments of interest, i.e., here Pol III loci, we consider the signal
akyi,k. Formally, from Equation 2,
bakyi;k = zi;kbkxi;k; ð3Þ
where bk is estimated from 400-bp genomic bin counts outside of
the regions being scored. In practice, using the observed back-
ground (Equation 1) we estimate them as the positive residuals of
the regression of ChIP counts zi,k on input counts:
dwi;k := max 0;bakyi;kÞ: ð4Þ
The above scoring scheme is applied to calculate preliminary signal
counts in both human and mouse samples independently.
Note that the principle of the SAP can also be performed suc-
cessfully with simple log ratio scores (of ChIP with input, data not
shown), as well as SPP scores (Fig. 6; Kharchenko et al. 2008).
Analysis method principle: determination of the spike
adjustment factor
For the spike chromatin, we expect that background-adjusted
counts should in principle be identical from sample to sample and
that any difference reflects technical experimental variations. Thus,
we use the human spike chromatin to compute a scaling factor to
adjust for different yields in specific background-subtracted counts.
Let dwi;k and dwi;r be the set of positive residuals computed from
Equation 4 for a single sample k and a reference r. In practice, as
reference we take the mean of positive residuals across all samples.
Then the spike-adjustment scaling factor for sample k can bewritten
using the means of signals in spike chromatin as
hk :=meank dwj;k meanr dwj;r  ¼ +jdwi;k.+jdwi;r; ð5Þ
where the index j is used instead of i to indicate that only a selected
set of regions with reliable signals in the spike material is used in
Equation 5.
The adjustment is then applied to the spike material for
quality control and to the experimental chromatin to obtain ad-
justed protein occupancy scores:
gwi;k := dwi;kchk; ð6Þ
where the tilde symbol (;) is used to refer to scores obtained after
spike adjustment. Thegwi;k values are non-negative and can be used
for analysis of relative occupancy in linear or log scale.
To obtain (log) ratios between the counts in the IP sample and
in the input sample, we use the estimator:
gLzi;k = log2 gwi;k +bkxi;k + pcbi;k + pc
 !
; ð7Þ
where the pseudo counts (pc) are typically set to one but can be set
higher to regularize ratios. In regions of high occupancy, gLzi;k is
positive, whereas in regions wheregwi;k is very small or zero, the log
ratio can be negative. These are the (log) scores we used in our
analysis (Figs. 4–6).
Analysis method principle: sequencing depth and spike
percentage
The calculation of the spike adjustment factor in Equation 6 is
based on the mean of the sum of n signals in regions that, for us,
correspond to annotated Pol III genes (whether or not occupied by
Pol III) and other previously identified Pol III–occupied loci
(Renaud et al. 2014). In principle, any set of known regions
enriched in the factor of interest can be used. The efficiency of
spike adjustment depends on sequencing depth and percentage of
spike material. Here we make an estimate of the standard error of
the adjustment factor considering the random variation of tag
sampling. The adjustment factor is the ratio of the estimated
means for the regions used (Equation 5). The sum of signals used
for correction can be estimated as such: For the data in Figure 5, the
sequencing depth is R » 1.33 108. The spike percentage is s = 2.5%,
and signal content in the entire sample, computed for our set of
700 loci, is p » 0.2%. Therefore, the total signal count sum is S =R3
s 3 p » 6500. Of the 700 human Pol III loci studied previously
(Renaud et al. 2014), we singled out about 500 significantly oc-
cupied loci, which account for >90% of all Pol III loci counts (S »
6000). Themean count per locus used for adjustment is thus about
S/n » 13, but it is the precision of S that determines the precision of
the adjustment factor. Under the classic Poisson assumption for
sampling error, the theoretical relative error r = sqrt(S)/S is about
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0.013. For the adjustment factor, which is the ratio of two such
quantities, the relative error is the double, thus ;2.5%. To halve
the theoretical relative error, one needs about four times more se-
quence tags, for example by increasing the proportion of the spike
material to s = 10%. If there are more counts in known sites in the
spike chromatin, say p = 10%, then one could reduce the spike
chromatin percentage or sequence less deeply. Exact conditions
need, however, to be determined for the specific parameters of
each experiment.
Data analysis: tag alignment
The 100-nt sequence tags obtained after ultra-high-throughput
sequencing were mapped onto the UCSC genome versions men-
tioned in Supplemental Tables S1, A and B, and S2, A and B, via the
eland_extended mode of ELAND v2e in the Illumina CASSAVA
pipeline v1.8.2. Only the tags with perfect matches, which repre-
sented >85%of the data, were kept for the analysis. Tags sequenced
more than 50 times were given a maximum score of 50.
For the Pol III samples, counts were assigned to previously
defined lists of human andmouse annotated Pol III genes and Pol
III–occupied loci (Tables S2 and S3 in Renaud et al. 2014). For each
locus the annotated RNA-coding region (e.g., tRNA) was extended
by 150 bp on each side. One tag sequence was worth one count,
and fractional counts were attributed in the case of a partial
overlap between tag and locus. For the Pol II samples, tag counts
were attributed in the same manner to regions extended by 250
bp on each side of the 22,572 annotated RefSeq TSSs (human),
and on 11,217 annotated TSSs selected to be separated by at least
1000 bp from any other annotated TSS or polyadenylation site
(mouse) (Le Martelot et al. 2012). The total numbers of tags, with
and without redundancy, aligned onto the mouse and human
genomes, as well as the numbers of tags falling in either mouse or
human Pol III loci, are listed in Supplemental Tables S1, A and B,
and S2, A and B.
Data analysis: normalization for sequencing depth
Wenormalized themouse and human tags separately.We took the
median of the total numbers of aligned tags across all the samples.
We used this median as a reference total count.We then scaled bin
counts in all samples to obtain a new total sample count equal to
the reference total count. The typical reference total count was 150
million tags for mouse and 3 million for human tags. The input
samples were normalized to the same total reference count as the
ChIP samples.
Data analysis: calculating preliminary scores
For the Pol III data, we calculated scores as the non-negative re-
siduals of the regression of ChIP bin counts versus input bin counts
(see Equations 2–4). For the Pol II data, we calculated spp scores
(Fig. 6). The regression coefficients fromEquation 3were estimated
based on genomic bin counts outside of the regions being scored.
For the Pol III experiments, we thus used a set of 400-bp bins
covering the genome (6,637,291 bins on the mouse genome and
7,739,205 on the human genome). For the Pol II experiments, we
used 500-bp bins (5,309,835 bins on the mouse genome and
6,191,402 on the human genome).We calculated tag counts for all
bins, for ChIP and input samples. After selecting bins that did not
overlap with the regions to be scored, we performed a robust linear
regression on ChIP versus input. We used the regression co-
efficients to computebakyi;k in regions to be scored. The valuesdwi;k;
which were background-adjusted, estimated the counts due to
specific immunoprecipitation.
Data analysis: calculation of the spike adjustment factor
and score adjustment
We used either a subset or all of the scored regions in the spike
chromatin to calculate the score adjustment factor. Subselecting is
inherent to our scoring method, since we select positive residuals
only and set negative residuals to zero. Depending on the data
analyzed, it might be appropriate to take upper quantiles or use
a threshold score. The spike adjustment scaling (h) between two
samples k and r was then computed as
hk =
+j dwi;k
+jdwi;r ;
where the w^’s were the preliminary scores in the human
regions j for these two samples. The index r here indicates a ‘‘ref-
erence’’ sample. The spike adjustment factor h was then applied
as scaling factor to adjust the corresponding mouse gene scores:gwi;k =dwi;khk. The example above considers the spike adjustment
of one sample k with respect to a reference sample r. In practice,
we adjusted multiple samples together. In our analysis and all
figures, the reference was taken to be themean of means of scores
in all samples.
Data analysis: final scores for follow-up analysis
After spike adjustment, for final quantification we used the ad-
justed log ratios, as shown in Equation 7. The adjusted gene scores
~w are still in linear scale. We re-added the estimated background
and then took a log ratio with the observed background. These
final scores were used in all figures in this manuscript.
Data access
The data from this study have been submitted to the NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo)
under accession number GSE52049.
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